Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/342525
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | New perspectives for pharmacological chaperoning treatment in methylmalonic aciduria cblB type |
Autor: | Brasil, Sandra CSIC ORCID; Briso-Montiano, Álvaro CSIC ORCID; Gámez, Alejandra CSIC ORCID; Underhaug, Jarl; Flydal, Marte I.; Desviat, Lourdes R. CSIC ORCID; Merinero, Begoña CSIC; Ugarte, Magdalena CSIC ; Martínez, Aurora; Pérez, Belén CSIC ORCID | Palabras clave: | Pharmacological chaperones MMA cblB type ATR MMAB Destabilizing mutations |
Fecha de publicación: | feb-2018 | Editor: | Elsevier | Citación: | Biochimica et Biophysica Acta - Molecular Basis of Disease 1864(2): 640-648 (2018) | Resumen: | Methylmalonic aciduria cblB type (MMA cblB) is caused by the impairment of ATP:cob(I)alamin adenosyltransferase (ATR), the enzyme responsible for the synthesis of adenosylcobalamin (AdoCbl) from cob(I)alamin. No definitive treatment is available for patients with this condition and novel therapeutic strategies are therefore much needed. Recently, we described a proof-of-concept regarding the use of pharmacological chaperones as a treatment. This work describes the effect of two potential pharmacological chaperones - compound V (N-{[(4-chlorophenyl)carbamothioyl]amino}-2-phenylacetamide) and compound VI (4-(4-(4-fluorophenyl)-5-methyl-1H-pyrazol-3-yl)benzene-1,3-diol) - on six ATR mutants, including the most common, p.Arg186Trp. Comprehensive functional analysis identified destabilizing (p.Arg186Gln, p.Arg190Cys, p.Arg190His, p.Arg191Gln and p.Glu193Lys) and oligomerization (p.Arg186Trp and p.Arg191Gln) mutations. In a cellular model overexpressing the destabilizing/oligomerization mutations, compounds V and VI had a positive effect on the stability and activity of all ATR variants. When provided in combination with hydroxocobalamin a more positive effect was obtained than with the compounds alone, even in mutations previously described as B12 non-responsive. In addition, a normal oligomerization profile was recovered after treatment of the p.Arg186Trp mutant with both compounds. These promising results confirm MMA cblB type as a conformational disorder and hence, pharmacological chaperones as a new therapeutic option alone or in combination with hydroxocobalamin for many patients with MMA cblB. | Versión del editor: | https://doi.org/10.1016/j.bbadis.2017.11.024 | URI: | http://hdl.handle.net/10261/342525 | DOI: | 10.1016/j.bbadis.2017.11.024 | ISSN: | 1879-260X |
Aparece en las colecciones: | (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
1-s2.0-S0925443917304465-main.pdf | 1,04 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
10
checked on 26-abr-2024
WEB OF SCIENCETM
Citations
8
checked on 25-feb-2024
Page view(s)
40
checked on 27-abr-2024
Download(s)
6
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.